Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
14.40
+1.34 (+10.26%)
Streaming Delayed Price
Updated: 3:19 PM EDT, Jun 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
32
33
Next >
COMPASS Pathways Reports Q1 2023: Financials, Commercial Groundwork And Ongoing Phase 3 Trials
↗
May 11, 2023
Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent...
Via
Benzinga
Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials
↗
May 11, 2023
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated...
Via
Benzinga
Compass Pathways Plc (CMPS) Q1 2023 Earnings Call Transcript
↗
May 11, 2023
CMPS earnings call for the period ending March 31, 2023.
Via
The Motley Fool
Compass Pathways: Q1 Earnings Insights
↗
May 11, 2023
Via
Benzinga
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
COMPASS Pathways
Via
GlobeNewswire
Earnings Preview: Compass Pathways
↗
May 10, 2023
Via
Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
↗
May 08, 2023
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
Via
Benzinga
This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why
↗
May 06, 2023
Another piece of the regulatory puzzle fell into place, but there are plenty more.
Via
The Motley Fool
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations
↗
May 02, 2023
The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following Tuesday's approval of a joint application submitted by MAPS PBC and COMPASS...
Via
Benzinga
American Medical Association to Issue First New Code for Psychedelic Therapies
May 02, 2023
COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approved
From
COMPASS Pathways
Via
GlobeNewswire
April Psychedelic Drug Stocks Recap: The Ups And Downs
↗
April 30, 2023
Via
Talk Markets
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
↗
April 21, 2023
Via
Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
↗
April 20, 2023
Via
Benzinga
After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?
↗
April 20, 2023
Atai's stock is hurting, but its pipeline is still packed with promising programs.
Via
The Motley Fool
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
↗
April 19, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
↗
April 18, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
↗
April 17, 2023
Via
Benzinga
5 Short Squeeze Stocks To Watch: Getty Images, PaxMedica, A Mental Health Care Company And More
↗
April 17, 2023
Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the...
Via
Benzinga
Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder
↗
April 14, 2023
Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published...
Via
Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
↗
April 14, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
↗
April 13, 2023
Via
Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
↗
April 13, 2023
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space.
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
↗
April 12, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 11, 2023
↗
April 11, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
↗
April 10, 2023
Via
Benzinga
10 Short Squeeze Candidates: Getty Images Tops List, PaxMedica Rejoins Top Five, MicroStrategy Moves Up And More
↗
April 10, 2023
Potential short squeeze plays gained steam in 2021 and continued through 2023 with new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits...
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
↗
April 07, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 6, 2023
↗
April 06, 2023
Via
Benzinga
Compass Pathways, GH Research Among Top Psychedelic Movers Of Today
↗
April 05, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 4, 2023
↗
April 04, 2023
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
